Importantly, all types of IDH-mutant gliomas identified have in common that they have a significantly better outcome compared to malignant diffuse IDH-wildtype (IDH-wt) gliomas like glioblastoma, IDH-wt or IDH-wt/H3-mutant gliomas [32, 48]. This evidence concerns the gene IDH2 and central nervous system cancer.